He developed the world's first lung cancer vaccine

According to a reporter in London, scientists in the UK are using the same technology that created AstraZeneca's COVID-19 vaccine to develop the world's first vaccine capable of activating the immune system to kill bacteria. kills cancer cells and prevents lung cancer in people at high risk.

According to Sky News, scientists from Oxford University, Francis Crick Institute and University College London (UCL) developed the LungVax vaccine.

Scientists have developed the LungVax vaccine. (Photo: Shutterstock).

The vaccine works by using a DNA sequence to train the immune system to recognize and destroy 'red flag' proteins, or mutant antigens, in lung cancer cells.

Currently, the research team has received 1.7 million pounds ($2.14 million) from charities including Cancer Research UK and the CRIS Cancer Foundation to produce exported 3,000 doses of vaccine.

If LungVax tests trigger an immune response in a laboratory setting, the vaccine will move into clinical trials and then be tested on high-risk people.

Professor Mariam Jamal-Hanjani of UCL and the Francis Crick Institute, who will lead the LungVax clinical trial, said currently less than 10% of people with lung cancer survive 10 years after their disease.

This study complements existing efforts through lung screening to detect cancer earlier in those at highest risk.

LungVax may also offer a possible route to preventing some cancers detected in their early stages. However, Professor Jamal-Hanjani emphasized that the optimal solution to reduce the risk of lung cancer is to stop smoking.

According to Michelle Mitchell, CEO of Cancer Research UK, LungVax is a truly important step towards a future where cancer is more preventable.

According to data from Cancer Research UK, each year in the UK there are about 48,500 cases of lung cancer, 72% of which are due to smoking.